Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 4Phase 1/2 4Phase 2/3 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Radiation Pneumonitis 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Locally Advanced Gastric Cancer 1Esophageal Malignant Neoplasm, Local Recurrence 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced NSCLC 1Advanced Esophageal Cancer 1

Interventions

Paclitaxel 23Carboplatin 22Capecitabine 18Gemcitabine 16130-nm albumin-bound paclitaxel 16pembrolizumab 14Cyclophosphamide 12atezolizumab 9Epirubicin 9sacituzumab govitecan 8Albumin-Bound Paclitaxel 8eribulin 6Vinorelbine 6Drug Therapy 6Doxorubicin 6camrelizumab 4Docetaxel 4Cisplatin 4Injections 3pegfilgrastim 2olaparib 2famitinib 2Filgrastim 2Everolimus 2veliparib 1trilaciclib 1toripalimab 1taxane 1niraparib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Triple Negative Breast Neoplasms × camrelizumab × Clear all
NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
441 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Fudan University

Phase 3 Recruiting
424 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05760378 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Fudan University

Phase 3 Recruiting
223 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
80 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡